Tubulis and Bristol Myers Squibb Collaborate to Develop Next-Generation ADCs for Cancer Treatment

PatSnap Synapse, a novel, AI Powered Drug Competitive Intelligence database. Access to drugs, clinical trials, patents, literature and news in one search.

Tubulis, a German biopharmaceutical company, has announced a strategic license agreement with Bristol Myers Squibb (BMS) to develop differentiated antibody-drug conjugates (ADCs) for the treatment of cancer patients. Under the agreement, Tubulis will provide BMS access to its proprietary technology platform Tubutecan and P5, which enables the creation of site-specific conjugates with improved therapeutic properties.

Antibody drug conjugates are medicines that deliver highly potent chemotherapy agents to kill cancer cells with the potential for reduced damage to healthy. Unlike conventional chemotherapy treatments, which can damage healthy cells, antibody drug conjugates (ADCs) are targeted medicines that deliver chemotherapy agents to cancer cells. ADCs deliver the chemotherapy via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. After binding to the target (cancer protein or receptor), the ADC releases a cytotoxic drug into the cancer cell.

According to the Synapse drug intelligence database, the top five institutions in global ADC development progress are Takeda Pharmaceutical Co., Ltd., BSP Pharmaceuticals SpA, Rakuten Medical, Inc., GSK Plc, and Acino International AG. The top five targets in global ADC development progress are Tubulin, HER2, DNA, TOP1, and CD22. The top five indications in global ADC development progress are Breast cancer, HER2-positive breast cancer, Diffuse large B-cell lymphoma, Urothelial carcinoma, and HER2-positive gastric cancer.

Preview

来源: SYNAPSE

Bristol Myers Squibb Co. is a pharmaceutical company based in New York, United States, founded in 1887. It is publicly traded on the New York Stock Exchange under the symbol BMY. The company focuses on developing treatments for a range of diseases, including neoplasms, immune system diseases, digestive system disorders, and more. Their drug development efforts use various technologies, with small molecule drugs and monoclonal antibodies being the most commonly used. The company has also been developing drugs targeting specific proteins such as CRBN, BCMA, PD-1, CD19, and PDL1 in order to treat diseases.

Preview

来源: SYNAPSE

The collaboration between Tubulis and BMS represents a significant step forward in the development of next-generation ADCs for cancer treatment. By combining Tubulis' innovative technology platform with BMS' extensive experience in oncology drug development, the partnership aims to accelerate the discovery and development of more effective, safer, and accessible therapies for cancer patients.